Marc Yoskowitz

Marc Yoskowitz is a current Endo board member. He serves as Chief Executive Officer of Evozyne, Inc. a venture capital backed biotech designing novel proteins leveraging generative AI.  He has served as a member of the Board of Directors at Mereo BioPharma since 2022 where he is a member of the R&D Committee.  Previously he served as EVP and Chief Strategy Officer, Life Sciences at Tempus AI, Inc.  Prior to Tempus, Mr. Yoskowitz was Chief Business Officer, Pfizer Essential Health, leading a range of corporate initiatives within the Pfizer portfolio. Prior to Pfizer, he served as SVP, Strategy and Corporate Development at Hospira and was a member of the Executive Committee.  Earlier in his career, Mr. Yoskowitz led business development at a specialty pharmaceutical company, spent eight years at McKinsey & Company where he was an Associate Principal, and began his career as an M&A lawyer at Davis, Polk & Wardwell in New York.  Mr. Yoskowitz received a bachelor’s degree magna cum laude from Washington University in St. Louis and holds a J.D. from Columbia University School of Law. Mr. Yoskowitz was selected to serve on Endo’s board of directors based on his extensive leadership and management experience in the pharmaceutical industry.